Moderate to Severe Dry Eye Disease (DED) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Moderate to Severe Dry Eye Disease Emerging Therapy and TPP Insights

Thelansis’s “Moderate to Severe Dry Eye Disease (DED) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Moderate to Severe Dry Eye Disease Overview

Moderate to severe dry eye disease is a multifactorial disorder of the ocular surface characterized by loss of tear-film homeostasis, tear instability, inflammation, and, in some patients, epithelial damage. Meibomian gland dysfunction, aqueous deficiency, and neurosensory abnormalities contribute to different disease phenotypes and can produce discomfort, burning, photophobia, and fluctuating vision. Artificial tears remain foundational, but management has expanded substantially beyond lubrication to include anti-inflammatory therapies, tear-evaporation control, and stimulation of endogenous tearing. Established treatments now include cyclosporine, lifitegrast, perfluorohexyloctane, and the cholinergic nasal spray varenicline. The treatment landscape broadened further in 2025 with FDA approval of acoltremon, a TRPM8 agonist that stimulates tear production and improved tear-production endpoints in randomized trials. Next-generation development is increasingly focused on phenotype-specific mechanisms, including kinase inhibition and other approaches targeting ocular-surface inflammation, tear secretion, and glandular dysfunction. OT202, a dual SYK/VEGFR-2 inhibitor, demonstrated activity in a 2026 Phase 2 study and has entered Phase 3 development. For stakeholders, moderate to severe DED represents an increasingly segmented therapeutic market in which the next advances are likely to come from matching mechanism to phenotype and achieving more durable restoration of tear-film and ocular-surface homeostasis.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies – profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
• Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)